Mode
Text Size
Log in / Sign up

Review links periodontitis to higher cardiovascular risk but notes causal inference is unproven.

Review links periodontitis to higher cardiovascular risk but notes causal inference is unproven.
Photo by Marek Studzinski / Unsplash
Key Takeaway
Note that periodontitis associates with higher cardiovascular risk, but causal inference is unproven and event-level benefit remains investigational.

This narrative review examines the relationship between periodontitis and cardiovascular conditions, specifically atherosclerotic cardiovascular disease, coronary heart disease, and stroke. The scope includes an analysis of observational data where the population, sample size, and specific setting were not reported. The authors synthesize findings indicating that periodontitis is associated with higher risks for coronary heart disease, stroke, and cardiovascular mortality. These associations are characterized as modest but reproducible across the available literature.

The review highlights significant limitations inherent in the current evidence base. These include heterogeneous study designs, residual confounding, and the fact that interventional evidence is dominated by surrogate endpoints rather than hard clinical events. Furthermore, methodological challenges exist regarding microbiome- and genetics-based causal inference. Consequently, the authors state that event-level cardiovascular benefit from periodontal therapy remains unproven.

In terms of practice relevance, the findings motivate interdisciplinary exchange and research-facing collaboration. This approach integrates oral health assessment with immune and vascular phenotyping. However, clinicians must recognize that definitive causal inference is precluded due to the noted methodological issues, and the cardiovascular benefit from periodontal interventions remains investigational until validated by event-driven studies.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
Periodontitis is among the most prevalent chronic inflammatory diseases worldwide and may affect vascular health beyond the oral cavity. Framed within the concept of an oral–vascular axis, this review synthesizes clinical and mechanistic evidence linking periodontal disease with atherosclerotic cardiovascular disease (ASCVD). Epidemiological studies and meta analyses consistently associate periodontitis with higher risks of coronary heart disease (CHD), stroke, and cardiovascular mortality, with modest but reproducible effect sizes that persist after adjustment for traditional risk factors. However, heterogeneous study designs and residual confounding preclude definitive causal inference. Interventional evidence is currently dominated by surrogate endpoints, and event-level cardiovascular benefit from periodontal therapy remains unproven. Mechanistically, chronic periodontal inflammation may influence endothelial function and atherogenesis through interlocking pathways that can be viewed as a spatiotemporal, dual-regulatory network of immunity and metabolism: local dysbiosis and barrier disruption increase systemic access to microbial ligands and vesicular cargo, while systemic immune activation interacts with metabolic remodeling to shape inflammatory set-points and vascular susceptibility. Microbe-derived and host–microbe co-metabolites may further modulate redox balance, inflammatory tone, and vascular homeostasis within this network. We highlight limitations of existing interventional trials, methodological challenges in microbiome- and genetics-based causal inference, and priorities for translational research. Clinically, the oral–vascular axis motivates interdisciplinary exchange and research-facing collaboration that integrates oral health assessment with immune and vascular phenotyping, while recognizing that cardiovascular benefit from periodontal interventions remains investigational and requires event-driven validation.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.